ibandronate oral
Selected indexed studies
- Oral and intravenous ibandronate in the management of postmenopausal osteoporosis: a comprehensive review. (Curr Pharm Des, 2005) [PMID:16305506]
- Oral ibandronate in the management of postmenopausal osteoporosis: review of upper gastrointestinal safety. (Maturitas, 2006) [PMID:16522358]
- Daily oral ibandronate with adjuvant endocrine therapy in postmenopausal women with estrogen receptor-positive breast cancer: editorial commentary. (Ann Transl Med, 2024) [PMID:39118952]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Oral and intravenous ibandronate in the management of postmenopausal osteoporosis: a comprehensive review. (2005) pubmed
- Oral ibandronate in the management of postmenopausal osteoporosis: review of upper gastrointestinal safety. (2006) pubmed
- Daily oral ibandronate with adjuvant endocrine therapy in postmenopausal women with estrogen receptor-positive breast cancer: editorial commentary. (2024) pubmed
- Daily Oral Ibandronate With Adjuvant Endocrine Therapy in Postmenopausal Women With Estrogen Receptor-Positive Breast Cancer (BOOG 2006-04): Randomized Phase III TEAM-IIB Trial. (2022) pubmed
- Once-monthly oral ibandronate in postmenopausal osteoporosis: translation and updated review. (2009) pubmed
- Oral Ibandronate Therapy in Three Patients with Osteogenesis Imperfecta. (2021) pubmed
- A new concept for bisphosphonate therapy: a rationale for the development of monthly oral dosing of ibandronate. (2006) pubmed
- Cost-effectiveness of oral clodronate compared with oral ibandronate, intravenous zoledronate or intravenous pamidronate in breast cancer patients. (2008) pubmed
- Oral ibandronate in metastatic bone breast cancer: the Florence University experience and a review of the literature. (2010) pubmed
- Racial difference in bioavailability of oral ibandronate between Caucasian and Taiwanese postmenopausal women. (2020) pubmed